Profusa, Inc. PFSA
Medical/Dental Instruments · data as of November 13, 2026
Profusa, Inc. (PFSA) is a healthcare company listed in the US with a market value of about $271330.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.0. A discounted cash flow model with moderate assumptions puts its intrinsic value about 73% below the current price.
About Profusa
Profusa is listed in the US and classified in medical/dental instruments. It was profitable in 2 of the last 4 years in our data. Its share count rose by 1195% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- ROE above 15%
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | $100000 | — | — |
| Net income | -$36M | -$9M | $1M | $7M |
| Free cash flow | -$16M | — | — | — |
| EPS (diluted) | $-107.01 | $-357.14 | $24.12 | $60.29 |
| Net margin | — | -9230.0% | — | — |
| ROIC | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Profusa’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Is Profusa stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 73% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Profusa pay a dividend?
Not currently.
Is Profusa a good stock to buy?
We do not give buy or sell advice. Profusa scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.